Key highlights
- Full-year Revenue increased by 9% to £59.9 million, with second-half sales rising by more than 12%.
- Grassmuno, the company’s grass-pollen immunotherapy, launched in Germany in January 2026 and achieved encouraging early clinician uptake.
- The VLP Peanut Vaccine met its primary safety endpoint in a Phase I/IIa trial, supporting further clinical development.
- Cash more than doubled to £24.2 million following a refinancing that included a £40 million senior secured Facility from Hayfin.
- Despite the operational progress, the shares remain near 8p as investors weigh continued losses, Debt and financing risks.
Allergy Therapeutics (LSE:AGY), the AIM-quoted immunotherapy specialist, delivered a confident set of full-year results for the 12 months ended 30 June 2026. Revenue rose 9% to £59.9 million, second-half sales increased by more than 12%, and cash more than doubled to £24.2 million following a refinancing. Its German grass-pollen immunotherapy, Grassmuno, launched in January 2026 and achieved encouraging early clinician uptake, while its short-course peanut vaccine met a key Phase I/IIa safety endpoint. Even so, the shares have traded around 8p. With the company still loss-making and reliant on external financing, the precise cause of the latest share-price decline is unclear.
What happened?
On 29 July 2026, Allergy Therapeutics reported its full-year results for the 12 months ended 30 June 2026, capping a period of accelerating commercial momentum. The centrepiece was the launch of Grassmuno, its grass-pollen allergy immunotherapy, which went on sale in Germany in January 2026 and achieved encouraging early uptake among clinicians in the company’s most important market.
Alongside this commercial progress, the group advanced its clinical pipeline. Its short-course VLP Peanut vaccine met the primary safety endpoint in its Phase I/IIa trial and produced encouraging immunomodulatory data, supporting progression to the next stage of development. The company also said it was exploring a potential dual primary listing in Hong Kong to support its international expansion.
Despite the positive operational picture, the shares have traded around 8p. There was no obvious negative disclosure in the results, and the weakness may reflect profit-taking, continued losses or concerns about financing and potential dilution rather than a single identifiable catalyst.
The numbers investors need to know
For the year ended 30 June 2026, revenue increased by approximately 9% to £59.9 million. Second-half sales rose by more than 12% compared with the corresponding period, underlining a return to faster growth.
At the half-year stage, the company had reported revenue growth of 7% to £36.3 million and an operating loss before Research and Development expenditure of £2.5 million, reflecting continued Investment in product launches and clinical trials.
The Balance Sheet was materially strengthened during the year. Cash more than doubled to £24.2 million following a refinancing that included a new £40 million senior secured facility from Hayfin. The company also has access to an additional £50 million of undrawn shareholder-loan capacity. Exercises of warrants used to repay Shareholder loans helped reduce outstanding debt, although they also increased the number of shares in issue.
Management guided to double-digit revenue growth for the year ending June 2027, supported by a full selling season for Grassmuno and the completion of Germany’s Therapy Allergen Ordinance transition in October 2026.
Germany is the group’s most important market, making the timing of the Grassmuno launch significant. As the product was introduced in January 2026, partway through the commercial cycle, it contributed for only part of the 2025–26 financial year. The year ending June 2027 should therefore provide a clearer indication of its sales potential.
Why the market may be concerned
Despite improving revenue momentum, Allergy Therapeutics has yet to demonstrate sustainable profitability. The £2.5 million operating loss before R&D reported at the half-year stage illustrates the cost of funding product launches and clinical development. Investors are now likely to Demand evidence that revenue growth can translate into improved margins and cash generation.
The group’s reliance on external financing is another concern. The £40 million senior secured Hayfin facility and up to £50 million of shareholder-loan capacity strengthen liquidity, but they also introduce interest costs, Leverage and refinancing risk. Previous Warrant exercises and financing arrangements have also diluted existing shareholders.
Grassmuno’s early uptake is encouraging, but its larger commercial test will come during the year ending June 2027, when it will benefit from a full selling season. Meanwhile, clinical programmes such as the VLP Peanut vaccine remain several development stages away from potential regulatory approval and commercialisation.
Why bulls may see an opportunity
Supporters of the stock may see the Business approaching an operational inflection point. Revenue growth accelerated during the second half, Grassmuno achieved an encouraging launch, and the completion of Germany’s Therapy Allergen Ordinance transition in October 2026 could create a more supportive commercial environment.
The refinancing has reduced immediate funding pressure, with cash more than doubling to £24.2 million and substantial additional facilities available. If the company can maintain double-digit sales growth while controlling costs, its route towards sustainable profitability should become clearer.
The clinical pipeline provides additional long-term potential. The VLP Peanut vaccine targets a significant unmet medical need, and meeting its Phase I/IIa primary safety endpoint supports continued development. A potential Hong Kong listing could also broaden the shareholder base and help finance international expansion.
What happens next?
The immediate focus will be the 2026–27 selling season, which represents the first full financial year of Grassmuno sales. Investors will watch whether the company can deliver its double-digit revenue-growth guidance and demonstrate a credible path towards profitability.
The completion of Germany’s Therapy Allergen Ordinance transition in October 2026 will be another important milestone. Investors will also monitor the VLP Peanut vaccine’s progression into further clinical development and any additional trial results.
Cash consumption, debt levels and the use of the company’s enlarged financing facilities will remain under scrutiny. Any further fundraising could revive dilution concerns, while progress towards positive Cash Flow would strengthen the investment case.
A concrete decision on the proposed Hong Kong dual primary listing could also affect sentiment and reshape the company’s shareholder base. More broadly, the market will want to see accelerating sales accompanied by narrowing losses.
Outlook
Allergy Therapeutics (LSE:AGY) is making tangible operational progress. Revenue rose 9% to £59.9 million, second-half sales accelerated, Grassmuno achieved an encouraging launch, and cash increased to £24.2 million following the refinancing. The VLP Peanut vaccine’s successful Phase I/IIa safety result also adds long-term clinical potential.
Nevertheless, the shares continue to trade around 8p as investors seek evidence of sustainable profitability. The company remains loss-making and dependent on substantial external financing, while its pipeline programmes still require further development and investment.
The first full selling season for Grassmuno and delivery of double-digit revenue growth in the year ending June 2027 will be crucial. If stronger sales translate into narrowing losses and improved cash generation, the operational momentum could begin to support a higher valuation.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...